XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.21.2

Goodwill and Intangible Assets | 9 Months Ended
--- | ---
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | GOODWILL AND INTANGIBLE ASSETS Goodwill The following table summarizes the changes in the carrying amount of goodwill for the nine months ended September 30, 2021:
(in millions) | Diagnostic |  | Other |  | Total
Beginning balance | $ | 272.3 |  |  | $ | 56.9 |  |  | $ | 329.2 |
Divestitures | (31.6) |  |  | (56.9) |  |  | (88.5) |
Translation adjustments | (1.0) |  |  | — |  |  | (1.0) |
Ending balance | $ | 239.7 |  |  | $ | — |  |  | $ | 239.7 |
During the quarter ended September 30, 2021, the Company completed the sale of Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit. See Note 16 for additional information on these divestitures. Intangible Assets Intangible assets have primarily consisted of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. As of September 30, 2021, the Company's intangible assets consist of only purchased licenses and technologies due to the completion of the sales of Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit. In connection with these sales, the Company sold $199.1 million in purchased licenses and technologies, $4.8 million in-process research and development intangible assets, $4.7 million in customer relationships, and $3.0 million in trademarks, resulting in an aggregate decrease of intangible assets of $120.0 million, net of $91.6 million in accumulated amortization. See Note 16 for additional information on these divestitures. The following summarizes the amounts reported as intangible assets:
(in millions) | Gross Carrying Amount |  | Accumulated Amortization |  | Net
At September 30, 2021: |  |  |  |  |
Purchased licenses and technologies | $ | 617.4 |  |  | $ | (202.6) |  |  | $ | 414.8 |
Total amortized intangible assets | 617.4 |  |  | (202.6) |  |  | 414.8 |
Total intangible assets | $ | 617.4 |  |  | $ | (202.6) |  |  | $ | 414.8 |
(in millions) | Gross Carrying Amount |  | Accumulated Amortization |  | Net
At December 31, 2020: |  |  |  |  |
Purchased licenses and technologies | $ | 818.2 |  |  | $ | (248.2) |  |  | $ | 570.0 |
Customer relationships | 4.7 |  |  | (4.5) |  |  | 0.2 |
Trademarks | 3.0 |  |  | (1.5) |  |  | 1.5 |
Total amortized intangible assets | 825.9 |  |  | (254.2) |  |  | 571.7 |
In-process research and development | 4.8 |  |  | — |  |  | 4.8 |
Total unamortized intangible assets | 4.8 |  |  | — |  |  | 4.8 |
Total intangible assets | $ | 830.7 |  |  | $ | (254.2) |  |  | $ | 576.5 |
The Company recorded amortization expense during the respective periods for these intangible assets as follows:
| Three months ended September 30, |  | Nine months ended September 30,
(in millions) | 2021 |  |  | 2020 |  | 2021 |  |  | 2020
Amortization of intangible assets | $ | 11.6 |  |  |  | $ | 15.3 |  |  | $ | 40.6 |  |  |  | $ | 45.8 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration